P. Paluszek, P. Pieniazek, P. Musialek, T. Przewlocki, L. Tekieli, A. Kablak-Ziembicka, K. Dzierwa, M. Hlawaty, M. Trystula, P.
|
|
- August Perry
- 5 years ago
- Views:
Transcription
1 STenting for Ostial Vertebral Artery Stenosis (STOVAST Trial): Results from a prospective randomized study comparing bare-metal with drug-eluting stents. P. Paluszek, P. Pieniazek, P. Musialek, T. Przewlocki, L. Tekieli, A. Kablak-Ziembicka, K. Dzierwa, M. Hlawaty, M. Trystula, P. Podolec Institute of Cardiology, Jagiellonian University John Paul II Hosp., Krakow, Poland
2 Speaker s name: Piotr Paluszek I have the following potential conflicts of interest to report: Research contracts Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest
3 Strokes in the posterior circulation account for 25% to 35% of all ischemic cerebrovascular events¹. Symptomatic vertebral artery stenosis (VAS) is a well-known risk factor for vertebrobasilar (VB) stroke and carries a 10% to 15% incidence of stroke or death at 1 year ². The mortality associated with a VB stroke may be as high as 30%³!!! After a VB stroke or TIA, the risk of stroke within next 5 years without treatment is 25-35%³! ¹Stayman AN et al. A systematic review of stenting and angioplasty of symptomatic extracranial vertebral artery stenosis. Stroke Aug;42(8): ²Amin-Hanjani S et al., Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS): rationale and design. Int J Stroke Dec;5(6): ³Antoniou GA et al., Percutaneous transluminal angioplasty and stenting in patients with proximal vertebral artery stenosis. J Vasc Surg Apr;55(4):
4 The best treatment of patients with VAS is not clear: First line treatment: risk factors modification pharmacotherapy: statin + antiplatelet drugs Second line treatment: surgical treatment (low rates of stroke/death but high technical complexity is limiting!) endovascular therapy safe and valuable alternative
5 BUT!!! Baloon angioplasty is associated with a tremendously high restenosis rate (up to 100% - Cloud et al.) The use of bare-metal stents (BMS) is associated with high restenosis rate (up to 48% - Taylor et al.), limiting wider applicability of this treatment modality. It is not known whether drug-eluting stents (DES) in the ostial vertebral location can improve long-term results.
6 Author, year No. of patients No. of DES implanted Restenosis rate No. of BMS implanted Restenosis rate Song, % (3-year) % (3-year) Hatano, % (6-months) Chen, % (16-months) Zhou, % (12-months) Ogilvy, % (21 months) 35 38% (21 months) Jenkins, % (12-months) Werner, % (16-months) Paluszek, Pieniazek, % (12-months) 26 23% (12-months) Taylor, % (8-months) Gupta, (extracranial) Lugmayr, % (6-months) SSYLVIA Trial, % (VA) 43% (6-months)
7 Purpose: To prospectively evaluate angiographic and clinical outcome of stent-assisted vertebral artery angioplasty with a randomized allocation to DES vs BMS.
8 Material & Methods: 100 consecutive patients (65% men) with neurologist-confirmed diagnosis of symptomatic VAS External randomization to BMS vs. DES use. Duplex Doppler imaging and quantitative angiography (QA) prior to and immediately after stenting, and at one-year. QA evaluation performed by an independent Core Lab*, blinded to the BMS vs DES use. Technical success defined as <20% residual stenosis. Restenosis defined as an in-stent stenosis (ISR) > 50% diameter stenosis. *Krakow Cardiovascular Research Institute (KCRI)
9 VERTEBRAL ARTERY STENOSIS EVALUATION Fig. 1 Critical VA stenosis on Duplex Doppler Fig. 2 Critical VA stenosis on CT-angio
10 Angiography gold standard
11 100 patients: 49 DES (Ø , postdilated to 4.5mm as required angiographically): 19 zotarolimus-, 19 everolimus-, 6 paclitaxel-, 5 sirolimus-eluting 50 BMS (Ø mm): 35 stainless steel stents 15 cobalt-chromium stents
12 Clinical characteristics were not different between groups. Age History of VB Stroke History of VB TIA Drop attacks Severe vertigo/ dizziness Hyperten -sion Hyperlipidemia Type 2 diabetes Coronary artery disease Carotid artery disease DES (n=50) (12%) 7 (14%) 4 (8%) 45 (90%) 46 (92%) 43 (86%) 14 (28%) 42 (84%) 31 (62%) p BMS (n=50) (10%) 6 (12%) 4 (8%) 48 (96%) 48 (96%) 48 (96%) 12 (24%) 39 (78%) 35 (70%)
13 Immediate Results: Procedural success rate - 99% (in 1 patient RSA cannulation and RVA wireing were unsuccesful due to excessive access tortuosities) Technical success rate 100% Periprocedural VA stenosis severity was reduced from 74 ± 10.5% to 10 ± 5.5% (p<0.001) 1 transient global amnesia (TGA) occurred periprocedurally in the BMS-arm.
14 Results: 99 patients (100%) completed 1-month follow-up; 93% patients were asymptomatic (the only remaining symptoms were vertigo/dizziness). 93 patients (93.9%) completed one-year follow-up. 3 cardiac- and 1 cancer-death occurred in the DES-arm and 2 cardiac deaths in the BMS-arm. 1 new VB stroke occurred in the BMS-arm, 1 episode of VB TIA in the DESarm. Both ischaemic events were related to a significant progression of contralateral VAS! 63% patients remained asymptomatic at one-year.
15 Results (clinical): 1-month follow - up 1-year follow-up VB Stroke / TIA / Deaths Symptoms free Deaths VB TIA VB Stroke Symptoms free Consent for f/u angio withdrawn DES /45 2/45 (n=49) (0%) (93.9%) (8%) (2.2%) (0%) (66.7%) (4.4%) p BMS /48 6/48 (n=50) (0%) (92%) (4%) (0%) (2.1%) (60.4%) (12.5%) 8 patients withdrew follow-up angiography consent, 85 patients were thus available for one-year angiographic follow-up.
16 Results (angiographic): RVA / LVA Lesion Stent length Stent Direct length diameter stenting DES (n=49) 26 / ± 3.4 mm 11.5 ± 3.6 mm 3.49 ± 0.5 mm 36 p BMS (n=50) 22 / ± 2.2 mm 11.3 ± 2.3 mm 3.67 ± 0.5 mm 43
17 Results (angiographic - QA): Index stenosis severity In-stent lumen reduction directly after stenting In-stent lumen reduction after 12 mo (including restenosis) In-stent lumen reduction after 12 mo (excluding restenosis) Stent occlusion Restenosis rate (>50% ISR) DES (n=49) 74.8 ± 10.8% 9.3 ± 4.6 % 31.9 ± 23.8% 22.7 ± 11.1% 3 (7%) 9 / % p BMS (n=50) 73.3 ± 10.4% 10.7 ± 6.2 % 38.6 ± 25.8 % 25.3 ± 9.6% 1 (2.4%) 10 / % In 1-year follow-up 2 cases of stent fracture were observed
18 Results (angiographic): DES BMS Stent type Stainless steel Paclitaxeleluting Sirolimuseluting Everolimuseluting Zotarolimuseluting Cobaltchromium No. of stents implanted Restenosis Restenosis rate 6 2/4 50% 5 1/5 20% 19 4/19 21% 19 2/ % 35 9/30 30% 15 1/12 8.3%
19 Results restenosis group: Stent length Stent diameter Index stenosis severity In-stent lumen reduction directly after stenting <12mm 12mm <3.5mm 3.5 mm <75% 75% <10% 10% DES (n=9) (11.1%) (88.9%) (44.4%) (55.5%) (77.8%) (22.2%) (66.7%) (33.3%) BMS (n=10) (60%) (40%) (10%) (90%) (80%) (20%) (20%) (80%) All (n=19) (36.8%) (63.1%) (26.3%) (73.7%) (78.9%) (21%) (42%) (57.9%)
20 RVA stenosis at the ostium A prior to stenting B - after DES implantation C - 12 mo outcome
21 In-stent restenosis in BMS A prior to stenting B after BMS implantation C ISR in BMS D after DES in BMS implantation
22 Conclusions: Vertebral artery stenting for symptomatic vertebral artery stenosis is safe. Results from this randomized trial show no evidence for instent restenosis reduction with DES vs BMS use at the ostial vertebral location. Cobalt-chromium stents may have the lowest restenosis rate, however this needs to be confirmed in further large-volume multicenter randomized trials.
Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis
Predictors of restenosis and cardiovascular events in patients undergoing percutaneous angioplasty for subclavian/innominate artery stenosis Tadeusz Przewlocki, Anna Kablak Ziembicka, Piotr Pieniazek,
More informationTailored carotid artery stenting
Tailored carotid artery stenting is associated with a low complication rate 30-day results from the continued TARGET-CAS study in 1133 consecutive procedures. Lukasz Tekieli, Piotr Pieniazek, Piotr Musialek,
More informationAdvances in the treatment of posterior cerebral circulation symptomatic disease
Advances in the treatment of posterior cerebral circulation symptomatic disease Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, School of Health
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More informationPrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!!
PrOspective multicenter study of carotid artery stenting Usinng mer Stent OCEANUS study!!! Prof Piotr Pieniazek MD PhD Jagiellonian University Institute of Cardiology, John Paul II Hospital Krakow, Poland
More informationThe presenter does not have any potential conflicts of interest to disclose
Carotid intima-media thickness as a predictor of multi territory atherosclerotic occlusive disease in patients with symptomatic subclavian artery obstruction Leszek Wrotniak 1, Anna Kabłak Ziembicka 1,
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #345 (NQF 1543): Rate of Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) Who Are Stroke Free or Discharged Alive National Quality Strategy Domain: Effective Clinical Care 2018
More informationThe PARADIGM Study. Jagiellonian University Dept. of Cardiac & Vascular Diseases. John Paul II Hospital, Krakow, Poland
Prospective evaluation of All-comer percutaneous carotid revascularization In symptomatic and increased-risk asymptomatic carotid artery stenosis using CGuard Micronet-covered embolic prevention stent
More informationEndovascular treatment for pseudoocclusion of the internal carotid artery
Endovascular treatment for pseudoocclusion of the internal carotid artery Daqiao Guo, Xiao Tang, Weiguo Fu Institute of Vascular Surgery, Fudan University, Department of Vascular Surgery, Zhongshan Hospital
More informationThe CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent
The CARENET all-comer trial using the CGuard micronet covered carotid embolic prevention stent 6 month data Piotr Musialek, MD DPhil FESC Jagiellonian University Dept. of Cardiac & Vascular Diseases John
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationZotarolimus-Eluting Stent for the Treatment of Recurrent, Severe Carotid Artery In-Stent Stenosis in the TARGET-CAS Population
316 J ENDOVASC THER CLINICAL INVESTIGATION Zotarolimus-Eluting Stent for the Treatment of Recurrent, Severe Carotid Artery In-Stent Stenosis in the TARGET-CAS Population Lukasz Tekieli, MD, PhD 1,3 ; Piotr
More informationBifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
More informationCorporate Medical Policy
Corporate Medical Policy Endovascular Therapies for Extracranial Vertebral Artery Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: endovascular_therapies_for_extracranial_vertebral_artery_disease
More informationVivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine
Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Institute The Oregon Clinic Disclosure I declare that neither
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationa physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers
The study a physician-initiated study investigating the RoadSaver stent in carotid lesions Dr. Michel Bosiers Conflict of interest have the following potential conflicts of interest to report: Consulting
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationCarotid Stenosis Decision-making
Carotid Stenosis Decision-making PHARMACOTHERAPY + INTERVENTION ISOLATED PHARMACOTHERAPY? Carotid Stenosis Decision-making PHARMACOTHERAPY + INTERVENTION ISOLATED PHARMACOTHERAPY RISK OF PROCEDURE Conventional
More informationSection: Surgery Effective Date: July 15, 2015 Subsection: Original Policy Date: June 19, 2015 Subject: Summary
Last Review Status/Date: June 2015 Page: 1 of 16 Summary Vertebral artery diseases, including atherosclerotic stenosis, dissections, and aneurysms, can lead to ischemia of the posterior cerebral circulation.
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More information2/7/
Disclosure Intracranial Atherosclerosis an update None Mai N. Nguyen-Huynh, MD, MAS Assistant Professor of Neurology UCSF Neurovascular Service February 7, 2009 Case #1 60 y.o. Chinese-speaking speaking
More informationInvasive treatment for carotid fibromuscular dysplasia
Original paper Invasive treatment for carotid fibromuscular dysplasia Łukasz M. Tekieli 1, Damian R. Maciejewski 1, Karolina Dzierwa 1, Anna Kabłak-Ziembicka 1, Michał Michalski 2, Magdalena Wójcik-Pędziwiatr
More informationZilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results
Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 24-Month Results Hiroyoshi Yokoi, MD, Fukuoka Sannou Hospital Fukuoka, Japan On behalf
More informationTCT mdbuyline.com Clinical Trial Results Summary
TCT 2012 Clinical Trial Results Summary FAME2 Trial: FFR (fractional flow reserve) guided PCI in all target lesions Patients with significant ischemia, randomized 1:1 Control arm: not hemodynamically significant
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Scott O. Trerotola, MD, for the Lutonix AV Investigators Stanley Baum Professor of Radiology Professor of Radiology in Surgery Associate
More informationOverview of Subclavian & Innominate Artery Interventions
TCT 2016 Washington, DC, USA Tuesday November 1st, 2016 Peripheral vascular interventions Overview of Subclavian & Innominate Artery Interventions Dr Jacques Busquet Vascular & Endovascular Surgery Paris,
More information. Michael B. Horowitz, M.D.
Transluminal Stent-Assisted Angioplasty of the Vertebrobasilar System. Michael B. Horowitz, M.D. Case #1 64 y.o male VB TIA on maximal medical therapy(will define later) PMH: HTN, PVD, CAD, COPD, GERD
More informationDisclosures. Carotid artery stenting. Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence
Disclosures Surveillance after Endovascular Intervention: When to Re-Intervene and What s the Evidence None 2015 UCSF Vascular Symposium Warren Gasper, MD Assistant Professor of Surgery UCSF Division of
More informationThe MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
More informationDESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
More informationLutonix AV Clinical Trial
Long Term Effects of LUTONIX 035 DCB Catheter Interim 24 Month Results Ta-Wei Su MD Vascular surgery CGMH Taiwan Disclosure I have the following potential conflicts of interest to report: Consulting Employment
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
More informationTreatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery
Treatment Considerations for Carotid Artery Stenosis Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery 4.29.2016 There is no actual or potential conflict of interest in regards to this presentation
More informationSubclavian and Vertebral Artery Angioplasty - Vertebro-basilar Insufficiency: Clinical Aspects and Diagnosis
HOSPITAL CHRONICLES 2008, 3(3): 136 140 ORIGINAL ARTICLE Subclavian and Vertebral Artery Angioplasty - Vertebro-basilar Insufficiency: Clinical Aspects and Diagnosis Antonios Polydorou, MD Hemodynamic
More informationComparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study
Comparison of transradial and transfemoral approach for carotid artery stenting: RADCAR study (RADial access for CARotide artery stenting) Zoltán Ruzsa MD PhD et al. TCT 2013 Disclosure Statement of Financial
More informationMAL NCVH,2016. Yaron Almagor M.D Director Interventional Cardiology, SZMC Jerusalem
MAL-024-14-01 NCVH,2016 Yaron Almagor M.D Director Interventional Cardiology, SZMC Jerusalem CAS Treatment CREST Data Carotid endarterectomy (CEA) associate with more MI Brott et al. NEJM, 2010;363 Carotid-artery
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationMichael Horowitz, MD Pittsburgh, PA
Michael Horowitz, MD Pittsburgh, PA Introduction Cervical Artery Dissection occurs by a rupture within the arterial wall leading to an intra-mural Hematoma. A possible consequence is an acute occlusion
More informationPresent & future of below the knee stenting
Session 5 Below the knee arteries & limb salvage Present & future of below the knee stenting M. Bosiers K. Deloose P. Peeters 1 PRESENT Clinical perspective whom to treat CRITICAL LIMB ISCHEMIA (CLI) 0
More informationIntravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty
LINC 2015 Global Expert Exchange Forum January 28, 2015 Intravascular Imaging Insights into the Mechanism of Action of Focal Force Balloon Angioplasty Sahil A. Parikh, M.D. Assistant Professor of Medicine
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationA Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention
A Data-driven Therapeutic Algorithm For Choosing Among Currently Available Tools For SFA Intervention William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia
More informationDrug Eluting Stents: Update
Drug Eluting Stents: Update B. Berekoven Research Coordinator Department of Vascular Surgery St. Franziskus Hospital Münster Head: Univ.- Prof. Dr. G. Torsello baerbel.berekoven@sfh-muenster.de Disclosure
More informationIN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationSafety and Feasibility of Drug-eluting Stent Implantation at Vertebral Artery Origin: The First Case Series in Asians
ORIGINAL ARTICLE Safety and Feasibility of Drug-eluting Stent Implantation at Vertebral Artery Origin: The First Case Series in Asians Yen-Hung Lin, 1 Chi-Sheng Hung, 4 Wen-Yi Issac Tseng, 2 Ren-Kwan Lee,
More informationSCAI Fall Fellows Course Subclavian/Innominate Case Presentation
SCAI Fall Fellows Course 2012 Subclavian/Innominate Case Presentation Daniel J. McCormick DO, FACC, FSCAI Director, Cardiovascular Interventional Therapy Pennsylvania Hospital University of Pennsylvania
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #344: Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Effective Clinical
More informationAlternative methods of drug delivery in BTK vessels Initial insights from the TANGO trial
Alternative methods of drug delivery in BTK vessels Initial insights from the TANGO trial Ehrin Armstrong, MD, FACC Colorado University School of Medicine VA Eastern Colorado Healthcare System Denver,
More informationPhotoablation and DCB in in-stent restenosis
Photoablation and DCB in in-stent restenosis Craig M. Walker, MD, FACC, FACP Clinical Professor of Medicine Tulane University School of Medicine New Orleans, LA Clinical Professor of Medicine LSU School
More informationIntracranial Atherosclerosis in Asians
Intracranial Atherosclerosis in Asians Anthony S. Kim, MD Assistant Clinical Professor of Neurology UCSF Neurovascular Service February 27, 2010 Disclosures Research Support National Institutes of Health
More informationPre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease
Pre-and Post Procedure Non-Invasive Evaluation of the Patient with Carotid Disease Michael R. Jaff, D.O., F.A.C.P., F.A.C.C. Assistant Professor of Medicine Harvard Medical School Director, Vascular Medicine
More informationHybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case
Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case Chernyavskiy M.,MD,PhD, Chernova D., Zherdev N., Chernov A. Almazov National Medical Research Centre, St.Petersburg, Russia
More informationIndex. interventional.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACAS (Asymptomatic Carotid Atherosclerosis Study), 65 66 ACST (Asymptomatic Carotid Surgery Trial), 6 7, 65, 75 Age factors, in carotid
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationSmooth muscle pharmacology & interventional cardiology
Smooth muscle pharmacology & interventional cardiology By: Pascal Bernatchez!!!!! LAST LECTURE Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationCarotid Artery Stenting
Carotid Artery Stenting Natural history of the carotid stenosis Asymptomatic 80% carotid stenosis - 6% risk of stroke / year Symptomatic carotid stenosis have 10% risk of CVA at one year and 40% at 5 years
More informationPiotr Musialek, MD DPhil. Jagiellonian University Dept. of Cardiac & Vascular Diseases John Paul II Hospital, Krakow, Poland
2 0 1 8 Update On Results With The CGuard MicroNet Covered Stent (InspireMD) For CAS: Does It Prevent Strokes: Does It Cause ISR Or Other Long-Term Problems: Can It Have Value In Other Vascular Beds? Piotr
More informationCase Report Coronary Artery Perforation and Regrowth of a Side Branch Occluded by a Polytetrafluoroethylene-Covered Stent Implantation
International Scholarly Research Network Volume 2011, Article ID 212851, 4 pages doi:10.5402/2011/212851 Case Report Coronary Artery Perforation and Regrowth of a Side Branch Occluded by a Polytetrafluoroethylene-Covered
More informationCoroflex ISAR. Sirolimus Eluting Polymer-Free Coronary Stent System. Vascular Systems
Coroflex ISAR Sirolimus Eluting Polymer-Free Coronary Stent System Vascular Systems Coroflex ISAR Polymer-Free Drug Coating Complete Drug Release Sirolimus Established anti-inflammatory and anti-proliferative
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationSAMMPRIS. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis. Khalil Zahra, M.D
SAMMPRIS Stenting and Aggressive Medical Management for Preventing Recurrent Stroke and Intracranial Stenosis Khalil Zahra, M.D Major points Patients with recent TIA or stroke and intra-cranial artery
More informationISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More informationXPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses
XPEDITE Clinical Study PaclitaXel-coated Peripheral StEnts used In the Treatment of FemoropoplitEal Stenoses Thomas Zeller, M.D. Universitäts-Herzzentrum Freiburg-Bad Krozingen, Germany Disclosure Speaker
More informationLow profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster
Low profile TEVAR: is it an added value? Michel Bosiers, G. Torsello Münster Disclosure Speaker name:...michel Bosiers... I have the following potential conflicts of interest to report: Consulting Employment
More informationCarotid Artery Stenting
Carotid Artery Stenting Woong Chol Kang M.D. Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Carotid Stenosis and Stroke ~25% of stroke is due to carotid disease, the reminder
More informationVertebrobasilar Insufficiency
Equilibrium Res Vol. (3) Vertebrobasilar Insufficiency Toshiaki Yamanaka Department of Otolaryngology-Head and Neck Surgery, Nara Medical University School of Medicine Vertebrobasilar insufficiency (VBI)
More informationClinical Study Endovascular Recanalization for Chronic Symptomatic Intracranial Vertebral Artery Total Occlusion
Minimally Invasive Surgery, Article ID 949585, 6 pages http://dx.doi.org/10.1155/2014/949585 Clinical Study Endovascular Recanalization for Chronic Symptomatic Intracranial Vertebral Artery Total Occlusion
More informationSurgical Bypass or. Zilver PTX. 12 months preliminary data. LINC 2016, Leipzig. Marc Bosiers, MD. Marc Bosiers Koen Deloose Joren Callaert
LINC 2016, Leipzig Surgical Bypass or A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Patrick Peeters Jürgen Verbist Wouter Van den Eynde OLV Hospital,
More informationCarotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO
Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Goal of treatment of carotid disease Identify those at risk of developing symptoms Prevent patients at risk from developing symptoms Prevent
More informationRecanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion
Recanalization of Chronic Carotid Artery Occlusion Objective Improvement Of Cerebral Perfusion Paul Hsien-Li Kao, MD Assistant Professor National Taiwan University Medical School and Hospital ICA stenting
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationCurrent Non-Surgical Cardiac Interventions. By Pam Bayles, RN, BSN
Current Non-Surgical Cardiac Interventions By Pam Bayles, RN, BSN Balloon Angioplasty & DES A balloon-tipped catheter was first used in 1964 to treat a cause of atherosclerotic disease in a patient s leg
More informationFrom interventional cardiology to cardio-neurology. A new subspeciality
From interventional cardiology to cardio-neurology. A new subspeciality in the future? Prof. Andrejs Erglis, MD, PhD Pauls Stradins Clinical University Hospital University of Latvia Riga, LATVIA Disclosure
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationCAROTID ARTERY ANGIOPLASTY
CAROTID ARTERY ANGIOPLASTY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationCarotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA
Carotid Artery Stenting (CAS) Carotid Artery Stenting for Stroke Risk Reduction Matthew A. Corriere MD, MS, RPVI Assistant Professor of Surgery Department of Vascular and Endovascular Surgery Rationale:
More informationDETECT-PAD Computerized and patient specific model to determine pressure gradients in borderline iliac artery stenosis with MRA/ CTA
DETECT-PAD Computerized and patient specific model to determine pressure gradients in borderline iliac artery stenosis with MRA/ CTA Jean-Paul P.M. de Vries Head Department of Surgery University Medical
More informationTIA SINGOLO E IN CRESCENDO: due diversi scenari della rivascolarizzazione urgente carotidea
TIA SINGOLO E IN CRESCENDO: due diversi scenari della rivascolarizzazione urgente carotidea R. Pini, G.L. Faggioli, M. Gargiulo, E. Pisano, A. Pilato, E. Gallitto, C. Mascoli, L.M. Cacioppa, A. Vacirca,
More informationCarotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014
Carotid Artery Revascularization: Current Strategies Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Disclosures None 1 Stroke in 2014 Stroke kills almost
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More informationThe results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
More informationSmooth muscle pharmacology & interventional cardiology
LAST LECTURE Smooth muscle & interventional cardiology By: Pascal Bernatchez Classic Vascular -chronic -systemic Local Vascular -acute -targeted High blood pressure Blood pressure control Atherosclerosis
More informationCAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital
CAROTID STENTING A 2009 UPDATE Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital TREATMENT FOR CAROTID STENOSIS Best medical management Antiplatelet therapy Antihypertensive
More informationMassimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany
Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results
More informationΑγγειοπλαστική σε Eπαναστενωτικές Bλάβες
Αγγειοπλαστική σε Eπαναστενωτικές Bλάβες Βάιος Π. Τζίφος Δ/ντής Γ Καρδιολογικής Κλινικής - Επεμβατικής Καρδιολογίας. Ερρίκος Ντυνάν HC The Mehran s Classification for BMS-ISR Prognostic Value Pattern (1)
More informationLutonix in AV fistula and Early look AV IDE trial data
Lutonix in AV fistula and Early look AV IDE trial data Jackie P Ho Dept of Cardiac, Thoracic & Vascular Surgery National University of Singapore NUHS, Singapore Lutonix in AV fistula and final AV IDE trial
More information